The CD70-CD27 Axis in Cancer Immunotherapy: Predictive Biomarker and Therapeutic Target.

Area of Science:

• Immunology
• Cancer Biology
• Immunotherapy

Background:

• The CD27-CD70 pathway normally aids T cell responses but can cause T cell dysfunction in chronic cancer interactions.
• Tumor expression of CD70, regulated by factors like hypoxia and EBV, is linked to T cell exhaustion and immunosuppression.
• CD27 on tumor-infiltrating T cells indicates dysfunction and regulatory activity.

Purpose of the Study:

• To explore the dual role of the CD27-CD70 axis in cancer immunity and immunotherapy.
• To evaluate therapeutic strategies targeting CD70 and the potential of soluble CD27 as a biomarker.

Main Methods:

• Review of preclinical and clinical studies on CD70-targeting therapies (e.g., antibody-drug conjugates, CAR T cells, mAbs).
• Analysis of soluble CD27 levels in patient plasma and correlation with immunotherapy outcomes.
• Investigation of factors regulating CD70 expression in tumors.

Main Results:

• Anti-CD70 therapies show promise, particularly in hematological malignancies, but lack specificity.
• High soluble CD27 levels correlate with resistance to anti-PD-(L)1 immunotherapy in renal cancer, melanoma, and NSCLC.
• Soluble CD27 absence may permit escalation of combined immunotherapy (anti-PD-1/anti-CTLA-4).

Conclusions:

• The CD27-CD70 axis presents a significant target for novel cancer immunotherapies.
• Soluble CD27 serves as a potential predictive biomarker for guiding immunotherapy selection and treatment intensity.
• Further research is needed to develop specific CD70-targeting agents and validate soluble CD27 as a biomarker.